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Abstract 
In the United States, cancer accounts for one out of every four deaths, and significant 
resources have been devoted to the improvement of diagnosis and treatment. Early and accurate 
diagnosis is critical in ensuring favorable outcome for the patient. Currently, the diagnosis and 
subtyping of numerous different cancers greatly rely on pathologist interpretation of patient biopsy 
samples. The importance of correctly subtyping a cancer is emphasized due to the differences in 
clinical outcome. This can be a challenging task since several of the diagnoses can have 
overlapping histological features. Through proteomic profiling of different cancer subtypes, 
biomarkers can be identified to facilitate diagnosis. This study describes a novel Liquid 
Chromatography Tandem Mass Spectrometry (LC-MS/MS) method for characterizing archived 
formalin fixed paraffin embedded tissue (FFPE), accumulated over two decades.  
Improved tissue staining to identify areas of interest on histological slides is a requirement 
for patient tissue use. Standard practice in pathology uses hematoxylin with eosin as a counter 
stain. However, this combination of stains is not feasible for proteomic studies due to eosin binding 
to proteins. Staining optimization was performed on reactive lymphatic tissue to test the ability to 
visualize the germinal center, mantle and interfollicular space. The studies show that toluidine blue 
is a suitable MS compatible counter stain in the visualization of lymph node structures. Mass 
spectrometry experimentation demonstrates that protein identification and quantitation through 
spectral counting are not affected by the use of this combination of stains.  
The second requirement for working with patient tissue is the ability to collect tissue from 
patient tissue slides for further sample processing. Biopsy samples are typically placed on 
positively charged glass slides. In cases where the tissue of interest is a minority in the total tissue 
on a slide, laser capture microdissection is used for specimen collection. Optimal LCM tissue 
capture requires special polyethylene naphalate (PEN) slides. Positive slides, used in standard 
pathology practice, are not amenable to laser capture and make tissue removal difficult. While 
mechanical collection of tissue with razor or scalpel is an option there are concerns of 
contamination due to the physical contact involved. A novel anionic detergent removal protocol 
was developed to neutralize the charge on the slide surface allowing for tissue release. An 
additional benefit to the use of anionic detergent is the ability to introduce endoproteases for 
protein digestion concurrent with tissue release. The final MS compatible sample can be collected 
by pipette from the slide surface for immediate MS analysis. Comparison of the collection of 
biopsy tissue using PEN slides, mechanical removal from positive slides and the novel on slide 
digestion/release approaches was conducted in this study. Patient tissue used for this study 
included normal lymph node, lung squamous cell carcinoma and thymoma subtypes A and B3. 
Our analysis showed consistent proteins coverage between the three methods. Quantitation by 
spectral counting revealed that protein abundances obtained from tissues processed by the 
mechanical and on slide digestion approaches were similar. Differences in protein abundance were 
noted, however, for the proteins obtained from PEN slices. The reason for this difference is 
hypothesized to be tissue association with the slide membrane.  
The optimized approach was applied to proteomic studies of human lung neuroendocrine 
and thymoma cancers, which have not been previously studied by proteomics. Direct tissues 
studies are essential as there are no cell lines that mimic these tumors. The proteomic analysis 
showed that lung neuroendocrine and thymoma subtypes can be distinguished based on protein 
difference.   
In summary, this methodology has enabled direct proteomic characterization of patient 
tissues in diseases where cell line models are lacking and diagnosis is histologically challenging 
and important to clinical outcome.  These new methods will allow researchers to transition from 
in vitro cell line model to in vivo studies expanding our knowledge of the etiology of cancer while 
advancing clinical diagnosis and treatment.  
Introduction 
Currently in the United States, 14.5 million Americans have a history of cancer. This year 
it is expected that 1.6 million new cases will be diagnosed and over half a million people will die. 
Cancer is the second highest cause of mortality in the US behind heart disease and accounts for 
one in four deaths.1 For many forms of cancer, the key to successful treatment and optimal outcome 
is early diagnosis and treatment. However, studies show that up to 60% of cancers are not 
diagnosed until after metastasis has occurred, greatly complicating therapy.2 In the past decade 
great progress has been made in high throughput technologies for assessment of the DNA, RNA 
and proteins of whole cells in a single experiment, ushering in the –omics era. While the scope of 
this paper is to discuss proteomic research, it is important to understand that the –omics are all 
interlinked and combined play an important role in the regulation of homeostasis in a cell. 
Genomics enables the global study of DNA which serves as the blueprint templates for RNA 
transcripts. The RNA transcripts, studied globally by transcriptomics, in turn are translated into 
proteins which serve as the effectors of many cellular functions. Proteomics research plays an 
important role in the clinical setting in two ways: biomarker discovery and therapeutic target 
discovery. Historically, genomics based biomarkers have been used in the diagnosis of disease 
through characterization of DNA shed by cells into the serum.2 Assays search for DNA fragments 
carrying specific mutations. However, this method has an inherent flaw: while a disease associated 
DNA mutation may exist in a given individual, that specific mutation may not be transcribed or 
translated into proteins. Hence, detection of the mutated DNA does not indicate the disease state 
is present potentially leading to false positives in testing. Furthermore, DNA assays do not reflect 
protein post-translational modifications that regulate protein function.3 Since proteins serve as the 
effectors of cellular function, a protein based approach demonstrating changes in protein structural 
abnormalities or quantity is a more accurate indicator of cellular dysfunction associated with 
disease. Also, a variety of drugs target proteins within a cell, as a means to either restore cellular 
homeostasis or activate cell death pathways to “cure” a disease.4 
Patient Tissues 
There are several advantages to the use of patient tissue over other model systems. Cell 
culture involving established cell lines has been a prominent source of research material over the 
years. However, there is debate on how well a cell line represents a human disease state.5 Cell lines 
lack contact and signaling from neighboring cells, such as soluble factors, extracellular matrix 
molecules and cell-cell communications, which can lead to differences in gene expression from 
tissues.6-8 Alternatively, xenografts involving the passage of human tumor cells into generations 
of mice has been used as a source of disease cells. However, this technique requires a large number 
of animals and is costly.8  
Patient tissue is an attractive source of material for disease research for many reasons. First, 
human disease is heterogeneous. Molecular profiles from the cells of two patients with the same 
diagnosis are likely to show important differences. Thus, through use of samples from several 
different patients, researchers can account for this heterogeneity. While cell lines do not take into 
account the extracellular signaling that takes place in tissues, patient tissue are samples taken from 
their native environment including all of the associated factors such as cell-cell signaling, 
extracellular matrix and systemic signaling molecules transported by the blood stream. Several 
diseases currently do not have a corresponding cell line, therefore, patient tissue must be used. 
Finally, patient tissue can be archived and stored for decades. This allows for the collection of rare 
disease specimens over time. Also, patient tissue with longer history allows for longitudinal patient 
information to be collected detailing treatment outcome and prognosis.9 Clinical patient data when 
combined with proteomic profiles is useful in the creation of retrospective studies. 
Patient tissue is collected during biopsies and surgical resection. Unused tissue are 
catalogued and can be stored for some time prior to usage for research. Freezing and Formalin 
Fixation and Paraffin Embedding (FFPE) are two predominant methods for tissue preservation and 
storage. Although it has been documented by many researchers that frozen tissue produces the best 
sample quality downstream for DNA, mRNA and proteins, tissue freezing is costly in space and 
energy storage. The tissues must be kept at -80º C and can only be stored for one year.10 Tissue 
freezing leads to loss of histological features, introducing challenges in the identification of areas 
of interest. Furthermore, collected patient tissue is typically not frozen unless experimental usage 
of the tissue is predetermined. The study described in this document uses FFPE tissue. FFPE 
storage involves the fixation of collected tissue in formalin (4% formaldehyde) then embedding in 
a paraffin block. FFPE tissue storage preserves tissue histology allowing for easy identification of 
tissue collection boundaries.11 The tissue blocks can then be sliced into thin slices and placed on 
positively charged SuperFrost Plus slides. Since patient tissue carries an inherent negative charge, 
the tissue is bound to the slide electrostatically without contaminating chemical adhesives. 
Bottom- Up Proteomics 
 There are several techniques for the study of proteomics using mass spectrometry. Top 
down proteomics involves the use of intact proteins for mass spectrometry while middle down 
proteomics examines long peptides.12 The mass spectrometry experiments described in this study 
involves the use of bottom up proteomics. In bottom up proteomics, proteins are digested into 
peptides and separated using liquid chromatography, then analyzed through tandem mass 
spectrometry. Tandem mass spectrometry collects peptide mass data (MS1) and peptide 
fragmentation data (MS2), in two back-to-back rounds of mass spectrometry. These data can then 
be used to obtain the peptide sequences leading to protein identification. Spectral counting is a 
label free quantitation method based on the principle that the number of spectra containing 
components of a given protein correlates with the abundance of that protein. The bottom up method 
is advantageous in the analysis of complex samples, such as the entire proteome of a cell, due to 
front end sample separation and protein quantitation.13   
 This manuscript outlines a process to take advantage of the wealth of patient samples 
collected by pathologists and preserved through FFPE techniques at several clinical institutions 
for disease research using bottom up proteomics. The techniques described will cover the 
visualization of tissue structures and the collection of tissue for the purposes of mass spectrometry 
proteomics.  
Methods  
Patient Tissue 
Patient tissue used for this study is formalin fixed paraffin embedded. Tissues mounted on 
polyethylene napthalate (PEN) slides (Zeiss) were cut at 10 microns thickness. Tissue mounted on 
SuperFrost Plus slides were cut at 4 microns thickness. Staining studies were performed using 
reactive lymph node tissue mounted on PEN slides. Tissue collection studies were performed using 
thymoma subtypes A and B3, lung squamous cell carcinoma and lymph node tissue mounted on 
both PEN slides and Plus slides. 
Deparaffination and Staining 
 Tissues were deparaffinized in three rinses of octane at 2 minutes each. Following 
deparaffinization, tissues were washed with decreasing gradients of ethanol: 100% (3 washes), 
90% and 70% at 2 minutes each. Samples were then rinsed in water twice prior to staining (2 
minutes). Stains were prepared in lock mailer tubes (Ted Pella Inc. 21096), slides are placed into 
stain for 5 seconds followed immediately by a 15 second water wash. Single staining was 
performed using hematoxylin (Vector H-3404) and toluidine blue (Fisher Scientific T161-25). 
This process was repeated for double staining. Staining process was completed through increasing 
ethanol gradients: 70%, 95% and 100% (2 washes) at 2 minutes apiece. 
Laser Capture Microdissection 
 Tissue collection for the staining experiment was performed using laser capture 
microdissection. Reactive lymph node tissue germinal center, mantle and interfollicular space were 
collected on a PALM Microbeam IV, release 4.2 (Zeiss) and pressure catapulted into digestion 
buffer of 0.5% Rapigest (Waters Corporation) in 50 mM ammonium bicarbonate. 
Mechanical Tissue Collection 
 Studies on tissue collection utilized mechanical tissue collection (macrodissection). In this 
study three cases of B3 thymoma was obtained from The Ohio State University Department of 
Pathology for comparative study of tissue collection methods. Thymoma subtype A, lung 
squamous cell carcinoma and lymph node tissue were utilized to study generalized effects of tissue 
collection methods. 
 The tissue collection process is summarized in Figure 1. Tissues were cut at 10 micron 
thickness and mounted onto PEN slides and deparaffinized and stained using the process described 
in the previous section. A single PEN slide mounted specimen was used for each of the tissue 
samples. An incision surrounding the tissue of interest was made in the PEN membrane allowing 
the tissue to be lifted and collected for further sample processing. Tissue placed on SuperFrost 
Plus slides were cut at a thickness of 4 microns in triplicate for each tissue specimen. Following 
deparaffination and staining samples were collected by mechanical removal or on-slide digestion. 
For mechanical removal, tissue surrounding the area of interest was removed using a scalpel. The 
slide is then washed in ethanol and the tissue of interest is collected using dissection tools.  
PEN and Mechanical Collection Sample Digestion and Preparation 
 Collected samples were dissolved in 0.5% Rapigest in 50 mM ammonium bicarbonate. 
Samples are boiled for 20 minutes then incubated for 2 hours at 60º C to reverse crosslinks from 
formalin fixation. For protein digestion 2 mg Trypsin (Promega) dissolved in 50 mM ammonium 
bicarbonate (pH ~7.4) was added to each sample. Samples were digested for 18 hours at 37º C. 
Rapigest and trypsin are inactivated through addition of acid lowering to pH ~2 and final peptide 
sample is dried and resuspended in 50 µL of HPLC water. 
On-Slide Digestion Sample Preparation 
On-slide digestion is a novel method described in this paper that combines the tissue 
collection and sample processing steps for maximum tissue collection with minimal outside 
contamination. Specimen tissues were cut to 4 microns thickness and mounted on Plus slides in 
quadruplicate. Following deparaffination and removal of tissues of non-interest, slides were placed 
in lock mailer tubes (Ted Pella Inc.) and boiled for 20 minutes then incubated at 60º C for two 
hours. On-slide digestion involved the direct deposition of 20 µL digestion buffer (0.5 % Rapigest) 
with typsin (2 mg per sample). Slides were incubated at 37º C for 18 hours in the digestion process. 
Peptides are collected through rinsing the slide (rinses) and coverslip using rinses of 50 µL of 50 
mM ammonium bicarbonate. Rapigest and trypsin were inactivated through addition of acid 
lowering the pH to ~2 and the final peptide sample was dried and resuspended in 50 microliters of 
HPLC water. 
HPLC and Mass Spectrometry 
 Sample separation was performed using a Dionex 3000 UltiMate system using a C18 
reverse phase column (Microm Bioresources Magic C18AQ, 200 µm x 150 mm, 200 Å). The 
mobile phases were water with 0.1% formic acid and acetonitrile with 0.1% formic acid. The 
HPLC gradient consisted of an increasing percentage of the acetonitrile mobile phase over 5 hours. 
Mass spectrometry data collection was performed using a Thermo Scientific LTQ Orbitrap XL 
mass spectrometer. Data analysis for protein identification and spectral count analysis was 
performed through an in-house search engine, MassMatrix, with a Swiss-Prot human protein 
database14-17.   
Detergent Removal of Tissue from Plus Slides 
 The effectiveness of detergent ability to remove patient tissue from Superfrost Plus slides 
was assessed using 2 anionic detergents (Rapigest and sodium dodecyl sulfate) and 2 nonionic 
detergents (NP40 and Triton X). The detergents were placed on slides then incubated for 18 hours 
at 37º C. The slides were then rinsed with water and assessed for tissue removal. 
Results 
 Experiments were performed to assess staining which allows for visualization of tissue 
histology that were compatible with mass spectrometry proteomics. Also, experiments compared 
the collection and sample preparation from PEN slides, mechanical tissue removal from 
SuperFrost Plus slides and a novel technique, on slide tissue digestion on SuperFrost Plus slides 
(Figure 1). 
Tissue Staining with Hematoxylin and Toluidine Blue 
 Tissue staining results showed that hematoxylin staining alone is not sufficient to visualize 
the different structures found within the reactive lymph node (Figure 2a and b). While using 
diluted hematoxylin has improved the visualization of tissue structures the mantle regions remains 
difficult to visualize. Use of toluidine blue allows for visualization of the germinal centers (Figure 
2c). When the tissue is first stained with hematoxylin then counter stained with toluidine blue all 
structures of the reactive lymph node can be discerned (Figure 2d). 
 Data analysis of mass spectrometry results demonstrate that there is a high degree of 
overlap in protein identification between the three compared staining methods: hematoxylin, 
toluidine blue and double staining using hematoxylin and toluidine blue (Figure 3a). Log- log 
plots of the spectral counts of the proteins identified comparing the toluidine blue single stain and 
the hematoxylin/ toluidine blue double stain shows a high degree of linear correlation (Figure 3b). 
Thus, the protein identification and spectral count quantitation of mass spectrometry data are not 
significantly affected by the different staining protocols tested. 
Tissue Collection using PEN and SuperFrost Plus Slides 
 Successful tissue collection from the SuperFrost Plus slides was documented through a 
series of slide scans (Data not shown). Tissue collected from PEN slides was treated as complete 
collection, as incisions circumscribing the tissue of interest were made and tissue was directly 
lifted off the slide supported by the PEN membrane. Correlation of the spectral count quantitation 
data between individual samples and grouped samples was performed (Figure 4a). Linear 
correlation of the log- log plots demonstrated that quantitation by spectral counting in mass 
spectrometry sample analysis was not adversely affected by the tissue collection process. Overlap 
between the three sample collection methods demonstrated that protein identification is 
independent of the method used (Figure 4b). 
Detergent Removal of Tissue from Plus Slides 
 It was hypothesized that anionic detergents will interact with the positively charged 
SuperFrost Plus slides allowing tissue release from the slide. Experimentally, slides were 
incubated with anionic detergents (Rapigest and SDS) and nonionic detergents (NP40 and Triton 
X). This experiment demonstrated that the anionic nature of the digestion buffer used in studies 
was critical to the successful removal of tissue from the SuperFrost Plus slides (Supplementary 
Figure 1). Tissue was removed by washing when incubated with anionic detergents but not with 
nonionic detergents. 
Discussion 
Due to the heterogeneous nature of human tissue, histological visualization of tissue and 
structures are required to separate tumor cells from adjacent tissue. The pathology gold standard 
for visualization is the use of hematoxylin and eosin staining. Hematoxylin is a naturally occurring 
stain that is oxidized into hematein and mixed with metal ions that carry a positive charge. As a 
result, it stains negatively charged molecules within cells, such as nucleic acids, a purple blue 
color. Eosin is a synthetic stain targeting positively charged structures within cells such as lysine 
and arginine residues found in proteins. The binding of eosin to proteins leads to an alteration of 
mass, interfering with the mass spectrometry process. Since coverslips are not used on slides 
destined for mass spectrometry proteomics, the issue is further complicated by darkening of 
stained tissue, leading to further loss of histological resolution. Historically, groups have used 
hematoxylin alone to stain tissues for mass spectrometry proteomics studies. However, in certain 
tissues the hematoxylin alone is insufficient in discerning the tissue structures, as demonstrated in 
reactive lymph nodes. Studies have shown that with a toluidine blue double stain lymph node 
structures are once again visible for sample collection. This suggests that combination staining 
using different stains, such as hematoxylin and toluidine blue, is a possible solution when working 
with difficult to visualize tissue structures.    
Tissue collection methodology for bottom up mass spectrometry proteomics poses an 
interesting challenge. Laser capture microdissection (LCM) is a great advancement in the 
collection of small amounts of tissue using a laser system for both cold ablation and laser 
catapulting ensuring samples of great purity. However, during biopsy or surgical resection of larger 
tumors, the material placed on slides are predominantly tumor, making LCM unnecessary and cost 
ineffective. Thus, there exists a need to improve upon existing manual microdissection and 
macrodissection techniques. One existing practices is use of the Polyethylene Napthalate (PEN) 
slides in LCM for manual dissection if the tissue of interest is determined to be large enough. 
However, while existing collections of FFPE tissue can be readily placed on SuperFrost Plus 
slides, the PEN slides require manual effort by a pathologist leading to time consuming sample 
preparation. Additionally, this study has shown slightly lower data quality in both protein 
identification and spectral counts possibly due to PEN membrane sequestering of tissue from 
proteases or PEN polymer contamination of mass spectrometry samples. Alternatively, researchers 
have collected patient tissue from SuperFrost Plus slides through scraping the tissue off for further 
sample processing. Due to the sensitivity of mass spectrometry, keeping specimens contamination 
free is essential. There exists concern around a dissecting instrument making physical contact with 
the tissue of interest. The proposed on-slide digestion has several advantages over existing 
methods. On-slide digestion can utilize patient tissue found on SuperFrost Plus slides, eliminating 
the PEN slide costs and pathologist workload. Also, on-slide digestion insures the digestion of the 
entire tissue sample while on the slide without mechanical contact from a dissection instrument, 
reducing the risk of contamination. In summary, on-slide digestion is a viable method for 
performing bottom up proteomic experiments using archived FFPE tissues. 
The power of this method was demonstrated in a biomarker discovery experiment 
involving thymoma subtyping. While the thymoma is neither the most common nor the highest 
source of cancer mortality it does not have a representative cell line, thus, it has never been 
characterized molecularly. Thymomas are divided into five subtypes with varying clinical 
outcomes ranging from 100% survival rate for thymoma type A to 40% survival rate for thymoma 
type B3. Current subtype diagnosis involves pathologist histological interpretation of diseased 
tissue. However, the overlapping histological features between the different subtypes make 
objective diagnosis challenging. Thus, there exists a need for a molecular assay for a definitively 
objective diagnosis. In this experiment, we tested the five different thymoma subtypes with six 
patient cases apiece using the methods described in this manuscript. Proteins were identified and 
quantified then sorted through cluster analysis of the different patient samples. Analysis shows 
grouping of the different subtypes, suggesting that proteomic assays for distinguishing different 
subtypes is a possibility (Figure 5). Also, several proteins which are known biomarkers or cancer 
therapeutic targets found in tumors of other parts of the body were successfully detected in our 
study as potential markers for thymoma subtyping. This study further demonstrates the value of 
the methods proposed in this manuscript for use with proteomics research in biomarker and 
therapeutic target discovery. 
Conclusion 
 The staining and tissue collection methods described in this manuscript address the 
challenge faced by researchers attempting to use archived FFPE tissue. These advancements will 
open the doors for proteomics research on FFPE tissue from previously uncharacterized diseases 
where cell lines are not readily available. 
Acknowledgements 
The project described was supported by Award Number Grant TL1TR001069 from the National 
Center For Advancing Translational Sciences. The content is solely the responsibility of the 
authors and does not necessarily represent the official views of the National Center For Advancing 
Translational Sciences or the National Institutes of Health. 
 
  
Figure 1: Tissue Collection Methods Experimental Schematic 
A. Collection of tissue from PEN slides. B. Mechanical collection of patient tissue from SuperFrost 
Plus slides using a dissecting instrument. C. On slide digestion of patient tissue. 
 
 
Figure 2: Tissue Staining of Reactive Lymph Nodes 
A. Hematoxylin and eosin stain of reactive lymph node tissue. H&E stains are the gold standard 
for staining in histology. B. Hematoxylin single stain. Note the lack of visibility of the tissue 
structures. C. Toluidine blue single stain. While the germinal centers can be visualized, the 
mantle region remains unclear. D. Hematoxylin and toluidine blue double stain. The germinal 
center, mantle and interfollicular space are visible using this staining method.  
 
 
  
Figure 3: Protein Identification and Spectral Count Quantitation in Reactive Lymph Nodes 
are Independent of Staining Method 
A. Venn diagram comparing the proteins identified between the three different staining methods: 
hematoxylin single stain, toluidine blue single stain and hematoxylin and toluidine blue double 
stain shows large overlap, indicating that the proteins detected are consistent in each of the 
sample staining methods. B. The log-log plots of the spectral counts compare the quantitation of 
proteins between the samples. The linear relationship indicates that the spectral counts between 
samples are comparable. 
 
 
 
Figure 4: Protein Identification and Spectral Count Quantitation in Reactive Lymph Nodes 
are Independent of Tissue Collection Method 
A. The log-log plots of the spectral counts compare the quantitation of proteins between the 
samples. Top: Spectral count comparisons between the three different tissue collection methods 
using cumulative data from three thymoma B3 specimens. Bottom: Spectral count comparisons 
between the collection methods using cumulative data from thymoma B3 and A, lung squamous 
cell carcinoma and lymph node tissue. The linear relationship indicates that the spectral counts 
between samples are comparable. B. Venn diagram comparing the proteins identified between 
the three different tissue collection methods: PEN slide, mechanical collection and on-slide 
digestion shows large overlap, indicating that the proteins detected are consistent across each of 
the sample collection methods. 
 
 
  
Figure 5: Cluster Analysis of Thymoma Subtype  
6 patient specimens for each of the thymoma subtypes were analyzed using the method described 
in this manuscript. Cluster analysis grouping showed the B3 specimens clustering together, 
suggesting that they can be distinguished proteomically. Proteins known to have biomarker or 
therapeutic target utility in other cancers were identified as differentially abundant across the 
thymoma samples, showing difference between the subtypes. 
 
  
Supplementary Figure 1: Tissue Collection from SuperFrost Plus Slides is Mediated by 
Anionic Detergents 
Incubation of patient tissue in anionic detergents (Rapigest and sodium dodecyl sulfate) and 
nonionic detergents (Triton X and NP40) followed by washes show that the tissue release from 
Plus slides only occurs in the presence of anionic detergents. This supports the hypothesis that 
the anionic detergents binds to the positively charged SuperFrost Plus slides mediating tissue 
release for collection. 
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